COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron
Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron. Commercial launch expected in Q4/2026 -
-
-
COMMUNIQUÉ DE PRESSE
Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research GmbH updates rating on Formycon AG (ISIN: DE000A1EWVY8) to Buy with a target price of €48. Analyst expects revenue to rebound in H2 and Q4 due to FYB202 and FYB206 developments -
-
-
COMMUNIQUÉ DE PRESSE
Horus Pharma becomes additional commercialization partner for Formycon's Eylea® biosimilar FYB203 in selected European countries under the brand name Baiama®
Horus Pharma partners with Formycon for Eylea biosimilar commercialization in Europe under Baiama brand. Agreement includes upfront payments and royalties for Klinge. Aflibercept treats nAMD
